VYNE Therapeutics
VYNE
44 hedge funds and large institutions have $4.77M invested in VYNE Therapeutics in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 4 closing their positions.
258% more capital invested
Capital invested by funds: $1.33M → $4.77M (+$3.44M)
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
22% more funds holding
Funds holding: 36 → 44 (+8)
9.12% more ownership
Funds ownership: 15.61% → 24.73% (+9.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$512K |
| 2 |
SC
Shay Capital
New York
|
+$454K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$401K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$102K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$77.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$285K |
| 2 |
ACA
Acorn Capital Advisors
New York
|
-$235K |
| 3 |
Jane Street
New York
|
-$30K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$25.8K |
| 5 |
CCM
Corsair Capital Management
New York
|
-$16.8K |
VYNE Hedge Fund Activity: Q4 2025 in Review
44 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2025, worth a combined $4.77M — up 258% from $1.33M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new VYNE positions and 4 closed out — a net gain of 8 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $512K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $285K sold.
- 44 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2025, up from 36 in Q3 2025.
- Funds reported $4.77M of VYNE Therapeutics stock for Q4 2025, up 258% quarter-over-quarter.
- 12 funds opened new VYNE Therapeutics positions in Q4 2025 and 4 closed out, a net change of +8 holders.
- The largest VYNE Therapeutics buyer in Q4 2025 was Anson Funds Management, an estimated $512K added.
- The largest VYNE Therapeutics seller in Q4 2025 was Baker Bros. Advisors, an estimated $285K sold.
Based on aggregated 13F filings for Q4 2025.